Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,707 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
Ángel Calleja M, Navarro A, Serratosa JM, Toledo M, Villanueva V, Subías Labazuy S, Gil A. Ángel Calleja M, et al. Among authors: gil a. Expert Rev Pharmacoecon Outcomes Res. 2022 Oct;22(7):1127-1136. doi: 10.1080/14737167.2022.2107507. Epub 2022 Aug 3. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 35904256 Free article.
Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
Villanueva V, Carreño M, Gil-Nagel A, Serrano-Castro PJ, Serratosa JM, Toledo M, Álvarez-Barón E, Gil A, Subías-Labazuy S. Villanueva V, et al. Among authors: gil nagel a, gil a. Epilepsy Behav. 2021 Sep;122:108222. doi: 10.1016/j.yebeh.2021.108222. Epub 2021 Aug 6. Epilepsy Behav. 2021. PMID: 34371462 Free article.
Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain.
Villanueva V, Serratosa JM, Toledo M, Ángel Calleja M, Navarro A, Sabaniego J, Pérez-Domper P, Álvarez-Barón E, Subías S, Gil A. Villanueva V, et al. Among authors: gil a. Epilepsy Behav. 2023 Feb;139:109054. doi: 10.1016/j.yebeh.2022.109054. Epub 2023 Jan 3. Epilepsy Behav. 2023. PMID: 36603345 Free article.
Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA).
Falip M, López González FJ, Martín-Herranz I, Merino-Bohórquez V, Montoya J, Rey Gómez-Serranillos I, Rodriguez Uranga JJ, Ruiz E, Sancho-López A, Trillo Mata JL, Antoni Vallès J, Álvarez-Barón E, Sabaniego J, Subías-Labazuy S, Gil A. Falip M, et al. Among authors: gil a. Epilepsy Behav. 2023 Aug;145:109350. doi: 10.1016/j.yebeh.2023.109350. Epub 2023 Jul 20. Epilepsy Behav. 2023. PMID: 37480633 Free article.
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A, Falip M, Sánchez-Carpintero R, Abad-Sazatornil MR, Poveda JL, Aibar JÁ, Cardenal-Muñoz E, Aras LM, Sánchez R, Sancho-López A, Trillo-Mata JL, Torrejón M, Gil A. Gil-Nagel A, et al. Among authors: gil a. Epilepsy Behav. 2022 Jul;132:108711. doi: 10.1016/j.yebeh.2022.108711. Epub 2022 May 16. Epilepsy Behav. 2022. PMID: 35588562 Free article. Review.
Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis.
Domingo C, Fernandez M, Garin N, Milara J, Moran I, Muerza I, Pacheco A, Teruel C, Bentley R, Subiran R, Gil A. Domingo C, et al. Among authors: gil a. Appl Health Econ Health Policy. 2023 Jan;21(1):119-130. doi: 10.1007/s40258-022-00770-9. Epub 2022 Nov 2. Appl Health Econ Health Policy. 2023. PMID: 36319945 Free PMC article. Review.
1,707 results